AtriCure Announces Upcoming Investor Conference Schedule
2013 Canaccord Genuity Medical Technology & Diagnostics Forum Piper Jaffray
2013 Annual Health Care Conference
WEST CHESTER, Ohio -- October 31, 2013
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device
provider, today announced that it will be participating in the following
upcoming investor conferences:
*The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at the
Westin Grand Central Hotel in New York on November 14, 2013.
*The Piper Jaffray 2013 Annual Health Care Conference at the New York
Palace Hotel on December 4, 2013.
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing
innovative products, professional education and support for clinical science
to reduce the economic and social burden of atrial fibrillation. AtriCure's
Synergy Ablation System is the first and only device approved by the Food and
Drug Administration (FDA) for the surgical treatment of Persistent and
Longstanding Persistent forms of Afib in patients undergoing certain open
heart procedures concomitantly (simultaneously). AtriCure's AtriClip^™ Left
Atrial Appendage (LAA) occlusion device is the most widely implanted device
for LAA management worldwide.Afib affects more than two million people
worldwide and is estimated to cost more than $6.5 billion annually in
healthcare expenses. The number affected by Afib is expected to grow to 12
million by 2050.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.